The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
Summary of product characteristics
(2013) · Pharmaceutical Medicine · doi:10.1093/med/9780199609147.003.0027 · Cited by 1,905
Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
Maurer, M., Rosén, K., Hsieh, H.-J., Saini, S., Grattan, C., Gimenéz-Arnau, A., Agarwal, S., Doyle, R., Canvin, J., Kaplan, A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215372 · Cited by 1,105
Self-citationMaurer, M., Weller, K., Bindslev-Jensen, C., Giménez-Arnau, A., Bousquet, P. J., Bousquet, J., Canonica, G. W., Church, M. K., Godse, K. V., Grattan, C. E. H., et al. (2011) · Allergy · doi:10.1111/j.1398-9995.2010.02496.x · Cited by 843
Self-citationMacGlashan, D. W., Bochner, B. S., Adelman, D. C., Jardieu, P. M., Togias, A., McKenzie-White, J., Sterbinsky, S. A., Hamilton, R. G., & Lichtenstein, L. M. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.3.1438 · Cited by 823
EAACI/GA2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria
Zuberbier, T., Asero, R., Bindslev‐Jensen, C., Walter Canonica, G., Church, M. K., Giménez‐Arnau, A., Grattan, C. E. H., Kapp, A., Merk, H. F., Rogala, B., et al. (2009) · Allergy · doi:10.1111/j.1398-9995.2009.02179.x · Cited by 731
Self-citationEAACI/GA²LEN/EDF/WAO guideline: management of urticaria
Zuberbier, T., Asero, R., Bindslev‐Jensen, C., Walter Canonica, G., Church, M. K., Giménez‐Arnau, A. M., Grattan, C. E. H., Kapp, A., Maurer, M., Merk, H. F., et al. (2009) · Allergy · doi:10.1111/j.1398-9995.2009.02178.x · Cited by 527
Self-citationEAACI/GA2LEN/EDF guideline: management of urticaria
Zuberbier, T., Bindslev‐Jensen, C., Canonica, W., Grattan, C. E. H., Greaves, M. W., Henz, B. M., Kapp, A., Kozel, M. M. A., Maurer, M., Merk, H. F., et al. (2006) · Allergy · doi:10.1111/j.1398-9995.2005.00962.x · Cited by 461
Self-citationOmalizumab-induced reductions in mast cell FcεRI expression and function
Beck, L. A., Marcotte, G. V., MacGlashan, D., Togias, A., & Saini, S. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.06.032 · Cited by 456
Saini, S., Rosen, K. E., Hsieh, H.-J., Wong, D. A., Conner, E., Kaplan, A., Spector, S., & Maurer, M. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.06.010 · Cited by 398
Self-citation
Cited by
Zuberbier, T., Aberer, W., Asero, R., Abdul Latiff, A. H., Baker, D., Ballmer‐Weber, B., Bernstein, J. A., Bindslev‐Jensen, C., Brzoza, Z., Buense Bedrikow, R., et al. (2018) · Allergy · doi:10.1111/all.13397 · Cited by 1,445
Self-citationZuberbier, T., Abdul Latiff, A. H., Abuzakouk, M., Aquilina, S., Asero, R., Baker, D., Ballmer‐Weber, B., Bangert, C., Ben‐Shoshan, M., Bernstein, J. A., et al. (2022) · Allergy · doi:10.1111/all.15090 · Cited by 1,263
Self-citationNew developments in mast cell biology
Kalesnikoff, J., & Galli, S. J. (2008) · Nature Immunology · doi:10.1038/ni.f.216 · Cited by 748
The diagnosis and management of acute and chronic urticaria: 2014 update
Bernstein, J. A., Lang, D. M., Khan, D. A., Craig, T., Dreyfus, D., Hsieh, F., Sheikh, J., Weldon, D., Zuraw, B., Bernstein, D. I., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.02.036 · Cited by 682
Saini, S. S., Bindslev-Jensen, C., Maurer, M., Grob, J.-J., Bülbül Baskan, E., Bradley, M. S., Canvin, J., Rahmaoui, A., Georgiou, P., Alpan, O., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.306 · Cited by 471
Self-citationEuropean S2k Guideline on Chronic Pruritus
Weisshaar, E., Szepietowski, J., Dalgard, F., Garcovich, S., Gieler, U., Giménez-Arnau, A., Lambert, J., Leslie, T., Mettang, T., Misery, L., et al. (2019) · Acta Dermato Venereologica · doi:10.2340/00015555-3164 · Cited by 405
BSACI guideline for the management of chronic urticaria and angioedema
Powell, R. J., Leech, S. C., Till, S., Huber, P. A. J., Nasser, S. M., & Clark, A. T. (2015) · Clinical & Experimental Allergy · doi:10.1111/cea.12494 · Cited by 377
Fajt, M. L., & Wenzel, S. E. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.12.1871 · Cited by 353
Zhao, Z.-T., Ji, C.-M., Yu, W.-J., Meng, L., Hawro, T., Wei, J.-F., & Maurer, M. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.12.1342 · Cited by 303
Self-citationMechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria
Kaplan, A. P., Giménez-Arnau, A. M., & Saini, S. S. (2017) · Allergy · doi:10.1111/all.13083 · Cited by 293
Self-citationMetz, M., Ohanyan, T., Church, M. K., & Maurer, M. (2014) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2013.08.011 · Cited by 274
Self-citationMaurer, M., Metz, M., Brehler, R., Hillen, U., Jakob, T., Mahler, V., Pföhler, C., Staubach, P., Treudler, R., Wedi, B., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.06.032 · Cited by 270
Self-citationWinthrop, K. L., Mariette, X., Silva, J. T., Benamu, E., Calabrese, L. H., Dumusc, A., Smolen, J. S., Aguado, J. M., & Fernández-Ruiz, M. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.02.002 · Cited by 259
Maurer, M., Staubach, P., Raap, U., Richter‐Huhn, G., Bauer, A., Ruëff, F., Jakob, T., Yazdi, A. S., Mahler, V., Wagner, N., et al. (2017) · Clinical & Experimental Allergy · doi:10.1111/cea.12900 · Cited by 131
Self-citationStaubach, P., Metz, M., Chapman‐Rothe, N., Sieder, C., Bräutigam, M., Canvin, J., & Maurer, M. (2016) · Allergy · doi:10.1111/all.12870 · Cited by 130
“Previous studies have shown the positive effect of omalizumab in reducing the number of angioedema-burdened days, measured as ‘angioedema-free days’ (10, 11).”
BackgroundResultSelf-citationAntihistamine‐resistant chronic spontaneous urticaria: 1‐year data from the AWARE study
Maurer, M., Raap, U., Staubach, P., Richter‐Huhn, G., Bauer, A., Oppel, E. M., Hillen, U., Baeumer, D., Reinhardt, M., & Chapman‐Rothe, N. (2019) · Clinical & Experimental Allergy · doi:10.1111/cea.13309 · Cited by 74
Self-citationOmalizumab therapy for mast cell-mediator symptoms in patients with ISM, CM, MMAS, and MCAS
Lemal, R., Fouquet, G., Terriou, L., Vaes, M., Livideanu, C. B., Frenzel, L., Barete, S., Canioni, D., Lhermitte, L., Rossignol, J., et al. (2019) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2019.03.039 · Cited by 70
Novel Biologicals for the Treatment of Allergic Diseases and Asthma
Tan, H.-T. T., Sugita, K., & Akdis, C. A. (2016) · Current Allergy and Asthma Reports · doi:10.1007/s11882-016-0650-5 · Cited by 68
Targeting IgE in Severe Atopic Dermatitis with a Combination of Immunoadsorption and Omalizumab
Zink, A., Gensbaur, A., Zirbs, M., Seifert, F., Suarez, I., Mourantchanian, V, Weidinger, S., Mempel, M., Ring, J., & Ollert, M. (2016) · Acta Dermato Venereologica · doi:10.2340/00015555-2165 · Cited by 67
Staubach, P., Metz, M., Chapman‐Rothe, N., Sieder, C., Bräutigam, M., Maurer, M., & Weller, K. (2018) · Allergy · doi:10.1111/all.13339 · Cited by 65
“improvements in symptoms and QoL observed in these CSU patients are consistent with previous CSU trials, where omalizumab led to a rapid decrease in CSU symptoms and QoL impairment.(12,13,21) In addition, a recent analysis of three phase 3 studies showed that omalizumab 300 mg significantly improved total DLQI scores…”
ResultSelf-citationYuan, W., Hu, S., Li, M., Yang, L., Liu, L., Zheng, M., Guo, Z., Song, Z., Zhang, C., Diao, Q., et al. (2022) · Dermatologic Therapy · doi:10.1111/dth.15303 · Cited by 36
Metadata
- Authors
- Kaplan, A., Ledford, D., Ashby, M., Canvin, J., Zazzali, J. L., Conner, E., Veith, J., Kamath, N., Staubach, P., Jakob, T., Stirling, R. G., Kuna, P., Berger, W., Maurer, M., & Rosén, K.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2013-07
- Volume
- 132
- Issue
- 1
- Pages
- 101-109
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2156152702
- Cited by
- 573
- References
- 22
- FWCI
- 43.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.